Walter M. Stadler to Receptors, Vascular Endothelial Growth Factor
This is a "connection" page, showing publications Walter M. Stadler has written about Receptors, Vascular Endothelial Growth Factor.
Connection Strength
0.751
-
Sorafenib. Curr Opin Oncol. 2006 Nov; 18(6):615-21.
Score: 0.287
-
New targets, therapies, and toxicities: lessons to be learned. J Clin Oncol. 2006 Jan 01; 24(1):4-5.
Score: 0.269
-
Targeted agents for the treatment of advanced renal cell carcinoma. Cancer. 2005 Dec 01; 104(11):2323-33.
Score: 0.067
-
A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer. Ann Oncol. 2023 08; 34(8):714-722.
Score: 0.056
-
Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis. J Clin Pharmacol. 2013 May; 53(5):491-504.
Score: 0.028
-
Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology. 2010 Oct; 76(4):923-6.
Score: 0.023
-
Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design. Clin Genitourin Cancer. 2007 Dec; 5(7):460-3.
Score: 0.019